Longitudinal study of CSF biomarkers in patients with Alzheimer's disease.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Electronic Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Alzheimer Disease/*cerebrospinal fluid ; Biomarkers/*cerebrospinal fluid; Aged ; Aged, 80 and over ; Amyloid beta-Peptides/cerebrospinal fluid ; Case-Control Studies ; Cohort Studies ; Female ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; tau Proteins/cerebrospinal fluid

Background: The CSF biomarkers tau and Abeta42 can identify patients with AD, even during the preclinical stages. However, previous studies on longitudinal changes of tau and Abeta42 in individual patients with AD and elderly controls report somewhat inconsistent results.
Methodology/principal Findings: We investigated the levels of tau and Abeta42 at baseline and after 1 year in 100 patients with AD. In a second cohort of 45 AD patients we measured the CSF biomarkers at baseline and after 2 years. Moreover, in 34 healthy elderly controls the CSF biomarkers were followed for 4 years. The baseline levels of tau were increased with >60% in AD patients compared to controls (p<0.001), while baseline Abeta42 levels were decreased with >50% (p<0.001). In the AD group followed for 2 years, tau increased with 16% compared to the baseline levels (p<0.05). However, the levels of tau were stable over 4 years in the controls. The levels of Abeta42 did not change significantly over time in any of the groups. In the patients with AD, tau was moderately associated with worse cognitive performance already at baseline (p<0.05).
Conclusions/significance: Tau and Abeta42 in CSF seem to reflect the underlying disease state in both early and late stages of AD. The slight increase in tau over time observed in the patients with AD is modest when compared to the relatively large difference in absolute tau levels between AD patients and controls. Therefore, these markers maintain their usefulness as state markers over time and might serve as surrogate markers for treatment efficacy in clinical trials.

Lancet Neurol. 2006 Mar;5(3):228-34. (PMID: 16488378)
Neurology. 2003 May 13;60(9):1495-500. (PMID: 12743238)
Arch Neurol. 1999 Jun;56(6):673-80. (PMID: 10369305)
Handb Clin Neurol. 2008;89:261-8. (PMID: 18631750)
Clin Chem. 2005 Feb;51(2):336-45. (PMID: 15563479)
Ann Neurol. 1998 Jul;44(1):17-26. (PMID: 9667589)
J Neurol Sci. 2006 Dec 21;251(1-2):124-8. (PMID: 17097109)
Dement Geriatr Cogn Disord. 2006;22(1):48-53. (PMID: 16682793)
Biol Psychiatry. 1999 Sep 15;46(6):750-5. (PMID: 10494442)
Neurology. 2007 May 8;68(19):1588-95. (PMID: 17287448)
Arch Neurol. 2007 Mar;64(3):343-9. (PMID: 17210801)
Lancet Neurol. 2008 Sep;7(9):779-86. (PMID: 18672400)
Dement Geriatr Cogn Disord. 2007;23(5):316-20. (PMID: 17374949)
Lancet. 2006 Jul 29;368(9533):387-403. (PMID: 16876668)
Neurology. 1984 Jul;34(7):939-44. (PMID: 6610841)
Mol Chem Neuropathol. 1995 Dec;26(3):231-45. (PMID: 8748926)
Neurology. 1999 Oct 22;53(7):1488-94. (PMID: 10534256)
Neurology. 2004 Feb 24;62(4):591-600. (PMID: 14981176)
Neurology. 2007 Sep 4;69(10):1006-11. (PMID: 17785669)
Neurosci Lett. 2007 May 23;419(1):18-22. (PMID: 17482358)
Dement Geriatr Cogn Disord. 2007;24(2):118-24. (PMID: 17622715)
Mol Psychiatry. 2004 Jul;9(7):705-10. (PMID: 14699432)
J Alzheimers Dis. 2007 Nov;12(3):255-60. (PMID: 18057559)
Brain. 2006 Nov;129(Pt 11):2856-66. (PMID: 16854944)
Neurobiol Aging. 2009 Feb;30(2):165-73. (PMID: 17646035)

0 (Amyloid beta-Peptides)
0 (Biomarkers)
0 (tau Proteins)

Date Created: 20090718 Date Completed: 20091110 Latest Revision: 20211020

20240628

PMC2707615

10.1371/journal.pone.0006294

19609443